Streetbeat News

Price Targets

EXC

Barclays analyst Eric Beaumont has maintained an Overweight rating on Exelon (NASDAQ:EXC) but has reduced the price target from $38 to $36.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 3:17 pm

DDOG

Datadog's stock (DDOG) is trading higher following Citigroup's reaffirmation of a Buy rating and an increase in the price target from $125 to $150.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 3:15 pm

REG

Evercore ISI Group analyst Steve Sakwa upgraded Regency Centers (NASDAQ:REG) from In-Line to Outperform and increased the price target from $69 to $71.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 3:07 pm

NWE

Guggenheim analyst Shahriar Pourreza has upgraded NorthWestern Energy Group (NASDAQ:NWE) from Sell to Neutral and set a price target of $47.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 3:04 pm

CNP

CenterPoint Energy (NYSE:CNP) received mixed analyst ratings in the latest quarter, with 3 somewhat bullish and 1 somewhat bearish. The average 12-month price target is $28.5, up from $28.25. Barclays, Keybanc, and Morgan Stanley provided recent evaluations, with price target adjustments reflecting updated views on the company's performance. CenterPoint Energy's financials show a slight revenue decline but strong profitability indicators like net margin and ROE. The company's market cap is below industry benchmarks, but it has a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:01 pm

SUI

Sun Communities (NYSE: SUI) has been reviewed by 7 analysts in the past three months, with mixed ratings ranging from bullish to indifferent. The average 12-month price target is $133.43, up 3.57% from the previous target. Analyst actions include both upgrades and downgrades, with price targets adjusted accordingly. Sun Communities is a residential REIT with a portfolio of 670 properties, showing a revenue growth of 5.06% as of September 30, 2023, but lagging behind industry peers. The company has a strong net margin of 16.73%, an ROE of 2.1%, an ROA of 0.92%, and a conservative debt-to-equity ratio of 0.98.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:01 pm

SR

Analysts have provided mixed ratings for Spire Inc (NYSE:SR) with 1 bullish and 5 indifferent ratings in the past three months. The average 12-month price target is $63.0, a 3.51% decrease from the previous $65.29. Analysts from firms including Mizuho, B of A Securities, RBC Capital, Morgan Stanley, Stifel, and Wells Fargo have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Spire's financials show a decline in revenue growth, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio, indicating potential challenges ahead.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:00 pm

ALLY

Seven analysts have recently published ratings on Ally Financial (NYSE:ALLY), with a mix of bullish to bearish sentiments. Over the past three months, ratings have included 2 bullish, 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish, with no bearish ratings. The 12-month price targets show an average of $36.29, a high of $47.00, and a low of $28.00, indicating a 19.65% increase from the previous average target of $30.33. Analysts from firms like Wells Fargo, Deutsche Bank, Barclays, Goldman Sachs, Morgan Stanley, Wolfe Research, and TD Cowen have adjusted their ratings and price targets, reflecting their views on Ally Financial's market position and financial performance. Ally Financial, a major consumer auto lender, has a diversified business model but has seen a -1.41% decline in revenue growth as of September 30, 2023, and faces challenges in ROE and ROA, despite a strong net margin and prudent debt management.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:00 pm

ADMA

ADMA Biologics (NASDAQ:ADMA) received mixed analyst ratings in the latest quarter, with 4 analysts offering views. The average 12-month price target is $6.5, up from $6.00, with a high of $9.00 and a low of $5.00. Analysts from Mizuho and HC Wainwright & Co. raised their price targets, while Cantor Fitzgerald maintained its rating. ADMA Biologics is a biopharmaceutical company focusing on plasma-derived biologics for immunodeficient patients. The company's financials show a revenue growth of 63.72%, a net margin of 3.81%, ROE of 1.72%, ROA of 0.74%, and a debt-to-equity ratio of 1.01.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:00 pm

AVA

Guggenheim analyst Shahriar Pourreza upgraded Avista Corporation (NYSE:AVA) from Sell to Neutral and set a price target of $34. This reflects a change in the firm's outlook on the stock, suggesting a more favorable view than previously held.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:55 pm